Ipsen SA (IPN) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.125x

Based on the latest financial reports, Ipsen SA (IPN) has a cash flow conversion efficiency ratio of 0.125x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€526.70 Million ≈ $615.77 Million USD) by net assets (€4.23 Billion ≈ $4.95 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IPN market cap for the company's overall valuation and market capitalisation.

Ipsen SA - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how Ipsen SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ipsen SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ipsen SA ranked by their cash flow conversion efficiency. Explore IPN cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Advanced Energy Industries Inc
NASDAQ:AEIS
0.058x
Klepierre SA
PA:LI
0.041x
Konfoong Materials International Co Ltd
SHE:300666
0.013x
Chime Financial, Inc. Class A Common Stock
NASDAQ:CHYM
0.148x
Insurance Australia Group Limited
F:NRM
0.010x
Crane Company
NYSE:CR
-0.063x
New York Times Company
NYSE:NYT
0.095x
Bollore SA
PA:BOL
0.000x

Annual Cash Flow Conversion Efficiency for Ipsen SA (2002–2024)

The table below shows the annual cash flow conversion efficiency of Ipsen SA from 2002 to 2024. View Ipsen SA (IPN) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €4.18 Billion
≈ $4.89 Billion
€915.50 Million
≈ $1.07 Billion
0.219x -3.32%
2023-12-31 €3.82 Billion
≈ $4.47 Billion
€865.90 Million
≈ $1.01 Billion
0.226x -22.22%
2022-12-31 €3.34 Billion
≈ $3.90 Billion
€971.40 Million
≈ $1.14 Billion
0.291x -12.34%
2021-12-31 €2.74 Billion
≈ $3.20 Billion
€909.20 Million
≈ $1.06 Billion
0.332x -8.12%
2020-12-31 €2.13 Billion
≈ $2.49 Billion
€771.30 Million
≈ $901.73 Million
0.361x +0.94%
2019-12-31 €1.75 Billion
≈ $2.05 Billion
€627.70 Million
≈ $733.85 Million
0.358x +15.62%
2018-12-31 €1.84 Billion
≈ $2.16 Billion
€570.90 Million
≈ $667.44 Million
0.310x +12.48%
2017-12-31 €1.54 Billion
≈ $1.80 Billion
€422.90 Million
≈ $494.41 Million
0.275x +18.02%
2016-12-31 €1.36 Billion
≈ $1.59 Billion
€317.80 Million
≈ $371.54 Million
0.233x +27.88%
2015-12-31 €1.23 Billion
≈ $1.43 Billion
€223.60 Million
≈ $261.41 Million
0.182x -20.74%
2014-12-31 €1.07 Billion
≈ $1.25 Billion
€245.80 Million
≈ $287.37 Million
0.230x +19.15%
2013-12-31 €973.70 Million
≈ $1.14 Billion
€188.10 Million
≈ $219.91 Million
0.193x +24.07%
2012-12-31 €926.25 Million
≈ $1.08 Billion
€144.22 Million
≈ $168.61 Million
0.156x -9.89%
2011-12-31 €1.02 Billion
≈ $1.19 Billion
€175.45 Million
≈ $205.11 Million
0.173x -26.56%
2010-12-31 €1.08 Billion
≈ $1.26 Billion
€253.91 Million
≈ $296.85 Million
0.235x -10.11%
2009-12-31 €984.35 Million
≈ $1.15 Billion
€257.62 Million
≈ $301.19 Million
0.262x +11.75%
2008-12-31 €868.49 Million
≈ $1.02 Billion
€203.41 Million
≈ $237.81 Million
0.234x +6.63%
2007-12-31 €801.11 Million
≈ $936.58 Million
€175.97 Million
≈ $205.73 Million
0.220x -51.20%
2006-12-31 €727.90 Million
≈ $851.00 Million
€327.63 Million
≈ $383.04 Million
0.450x +86.93%
2005-12-31 €621.10 Million
≈ $726.13 Million
€149.55 Million
≈ $174.84 Million
0.241x -44.79%
2004-12-31 €197.73 Million
≈ $231.17 Million
€86.23 Million
≈ $100.82 Million
0.436x -10.31%
2003-12-31 €311.65 Million
≈ $364.36 Million
€151.54 Million
≈ $177.17 Million
0.486x +18.78%
2002-12-31 €227.95 Million
≈ $266.50 Million
€93.32 Million
≈ $109.10 Million
0.409x --

About Ipsen SA

PA:IPN France Drug Manufacturers - Specialty & Generic
Market Cap
$15.02 Billion
€12.84 Billion EUR
Market Cap Rank
#2169 Global
#44 in France
Share Price
€155.90
Change (1 day)
+0.06%
52-Week Range
€111.50 - €172.90
All Time High
€172.90
About

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more